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    Abstract  
The aim of this study was to estimate the prevalence of body dysmorphic disorder 
(BDD) on an inpatient ward in the UK with a larger sample than previously studied 
and to investigate the value of a simple screening question during an assessment 
interview. Four hundred and thirty two consecutive admissions were screened for 
BDD on an adult psychiatric ward over a period of 13 months. Those who screened 
positive had a structured diagnostic interview for BDD. The prevalence of BDD was 
estimated to be 5.8% (C.I. 3.6-8.1%). Our screening question had a slightly low 
specificity (76.6%) for detecting BDD. The strength of this study was a larger sample 
size and narrower confidence interval than previous studies. The study adds to 
previous observations that BDD is poorly identified in psychiatric inpatients. BDD 
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was identified predominantly in those presenting with depression, substance misuse 
or an anxiety disorder. The screening question could be improved by excluding those 
with weight or shape concerns. Missing the diagnosis is likely to lead to inappropriate 
treatment.  
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1. Introduction  
Body dysmorphic disorder (BDD) is characterised by a preoccupation with a 
perceived defect(s) or flaw(s) in physical appearance that is either not noticeable or 
appears only slight to others. In addition, to fulfil the diagnostic criteria the 
preoccupation must be significantly distressing or cause impairment in social, 
occupational or other important areas of functioning. BDD is now classified within 
the obsessive compulsive and related disorders (OCRD) section of the Diagnostic and 
Statistical Manual of mental disorders 5
th
 Edition (DSM5) (American Psychiatric 
Association, 2013) and it is proposed to include the diagnosis in the same section of 
the revised version of International Classification of Diseases (ICD-11)(Veale and 
Matsunaga, 2014). BDD is more common than previously recognized with a 
prevalence of about 2% in the general population (Koran et al., 2008; Rief et al., 
2006). It may be a chronic disorder, which persists for many years if left untreated 
(Phillips et al., 2005b). There is a high rate of psychiatric hospitalisation, suicidal 
ideation and completed suicide (Phillips et al., 2005a; Phillips and Menard, 2006; 
Veale et al., 1996a). In addition, many resources are wasted on those who attend 
dermatological and cosmetic surgery settings (Phillips et al., 2000; Sarwer et al., 
1998; Veale et al., 2003). One setting where there may be a higher prevalence of BDD 
than there is in the community is psychiatric inpatients.  There have been two 
previous studies in the USA where the prevalence rate on an adult ward was reported 
as between 11 and 12.9% (Conroy et al., 2008; Grant et al., 2001). However a 
subsequent study in Germany found a much lower prevalence rate of 1.9% (Kollei et 
al., 2011). One inpatient study has been conducted on an adolescent psychiatric unit, 
which found a prevalence of 4.8% (C.I=3.3 – 10.1%) in 208 patients who had definite 
BDD (Dyl et al., 2006). What was striking in all these studies is that virtually all the 
patients identified as having BDD had not disclosed their symptoms to the treating 
psychiatrist. A self-report BDD screening questionnaire was used in Conroy et al. 
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(2008) and (Grant et al., 2001) but screening questionnaires are rarely adopted in 
routine clinical practice. We therefore decided to evaluate the usefulness of a single 
screening question that could be incorporated into a standard history taking by a 
psychiatrist. 
The aim of this study was therefore to determine (a) the prevalence rate of 
BDD in an inpatient setting in the UK, (b) how BDD presents in an in-patient setting 
and (c) the value of a screening question to detect BDD; and (d) to explore the reasons 
for non-disclosure of symptoms by patients.  
2. Methods 
2.1 Subjects and setting 
Four hundred and eighty two patients admitted to an adult ward over a period 
of 13 months. The study took place in the inpatient ward of a private psychiatric 
hospital in the UK.  In this setting, most patients are funded privately or by their 
insurer. Some are funded by the state, National Health Service, usually when there are 
no acute beds available in the local service.  
Inclusion: All consecutive patients admitted to the adult ward to either (i) a general 
adult psychiatry service (n = 285) or (ii) an alcohol rehabilitation unit (n = 147). 
Patients with anorexia nervosa are not generally admitted, as there is no formal eating 
disorder program.  
Exclusion:  
(i) Patients admitted to a national specialist service for severe treatment refractory 
BDD (Drummond et al., 2008),  
(ii) Repeat admissions, who had already been screened.    
2.2 Procedure   
After their routine intake diagnostic assessment by the consultant and staff 
psychiatrist on admission, all patients were asked by a different staff psychiatrist, 
experienced in the diagnosis and management of BDD with the following screening 
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question for BDD which is modified from Phillips (2005): “Some people worry a lot 
about their appearance. Do you worry a lot about the way you look and wish you 
could think about it less?” If they answered yes (and there was no obvious deformity 
or disfigurement), the BDD Diagnostic module was then used from the Structured 
Clinical Interview for DSM-IV disorders (SCID) (First et al., 1995) and the patient 
consented to participate in the study. Other diagnoses such as anorexia nervosa or 
bulimia nervosa, were exclude with the SCID whenever the interviewer had any 
suspicion of another disorder accounting for the symptoms of BDD. DSM-IV was 
used as the study began before the publication of DSM-5 (American Psychiatric 
Association, 2013). The main feature of concern was identified and if a diagnosis of 
BDD was made, an interview was conducted to determine what prevented the 
individual from voluntarily reporting the symptoms in their history to their treating 
psychiatrist.  The case was then discussed with the admitting psychiatrist and the case 
notes were reviewed to determine if any other diagnosis was more appropriate. 
Ethical permission was granted by East London Research Ethics Committee 
(reference 10/H0704/71).   
 2.3 Statistical Analysis  
 Because the focus of this paper was on an adult setting, we removed the data 
on adolescents (n=21) from the study by Grant et al. (2001) in order to compare 
prevalence across different settings (Table 1). 
3. Results 
Of the 482 patients admitted to the inpatient ward, seven (1.5%) were 
excluded as they were a planned admission on the specialist service for severe 
treatment refractory BDD. Forty-three patients (8.9%) were excluded as a result of 
being a repeat admission. This left a cohort of 432 patients, in whom the screening 
question was asked.  
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Screening Question  
Answering “yes” to the screening question was a false positive in 95 out of the 
432 (22%). Of these, 67 patients had body weight or shape concerns but did not fulfil 
criteria for BDD or for anorexia nervosa or bulimia nervosa. The remaining 28 out of 
the 95 had other concerns such as worries about their face or appearance in general 
but did not fulfil criteria for BDD. The specificity of the screening question was 
therefore 76.6% (C.I 72.2 -80.7%).  
In the cohort of 432 patients, twenty-five (5.8%, CI 3.6-8.1) were identified at 
a diagnostic interview as having BDD. The demographic details and diagnoses of all 
the patients admitted on the ward are provided in Table 1 and compared against three 
previous studies in adult inpatient settings.  
Demographics of BDD  
Of those diagnosed with BDD in this study, sixteen were female and 9 were 
male. Seven were married, 4 were single in a long-term relationship, 9 single, 1 
widowed, and 4 had missing data. The mean age was 37 (SD 12.86). Twenty-two 
were Caucasian, one was Asian, one was Chinese, one was of mixed race. The main 
preoccupation was as follows: face in general including the skin (7), hair (4), eyes (2), 
skin (2), nose (2), teeth (2), height (1), breasts (1), ears (1), muscles (1), eyebrows (1), 
and genitalia (1).  
Admitting diagnoses  
The admitting psychiatrist recorded the following ICD10 diagnoses in those 
with BDD: substance use (9); depressive episode (6); anxiety disorder (6, of whom 2 
had generalized anxiety disorder, 1 had panic disorder, 3 had a mixed anxiety and 
depressive disorder); hypomania (2); bulimia nervosa (2). None had been identified as 
having BDD by the admitting psychiatrist.  
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Thirteen out of 21 (62%) patients said their symptoms of BDD were either 
their main problem or one of their main problems for which they wanted help. Five 
(24%) stated it was not their main problem but still wanted help for it. Three (14%) 
did not think it was their main problem and did not want help as they were managing 
by using avoidance or camouflaging behaviours.  
The main reasons for not disclosing their symptoms of BDD were identified in 
Table 2. The most common reason was shame or lack of knowledge of the symptoms 
of BDD as a recognized condition.  
4. Discussion   
This study is the first to identify the prevalence of BDD in a psychiatric 
inpatient setting in the UK and found a prevalence rate of 5.8% (CI 3.6-8.1%).  The 
strengths of the study are a larger sample size and narrower confidence interval than 
the 3 previous studies. This study adds to previous observations that BDD is poorly 
identified in psychiatric inpatients. None of the patients revealed their symptoms of 
BDD during a routine history. This was mainly because of shame or lack of 
knowledge about BDD or its treatment, or a desire to avoid the problem.  
There is a significant discrepancy in prevalence between the German study 
(Kollei et al., 2011) and those in the USA(Conroy et al., 2008; Grant et al., 2001). 
Kollei et al. (2011) noted that the differences may be related to (a) the relatively small 
sample sizes and wide confidence intervals in each of the studies, (b) lower frequency 
of the diagnosis of depression and substance misuse in the German sample, (c) the 
fact that the American sample were first screened using a questionnaire. Also of note 
is that the studies in the USA excluded those who did not consent to participate (for 
example if they lacked capacity or they were not interested in research). However, if 
there were no patients with BDD in those excluded in the American samples, it would 
have reduced the prevalence to 10.8% (Grant et al., 2001) to 11.2% (Conroy et al., 
2008). We might have expected a higher rate of BDD in those identified with 
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substance misuse. Substance misuse was diagnosed in 50.8% of the sample in Grant 
et al. (2001) and only 2% of Conroy et al. (2008).  
This study adds to the 3 previous ones, as there was a much larger sample size. 
The prevalence rate in in-patient settings is likely to vary depending on the diagnostic 
intake. However, the main message is that the prevalence across all four settings is 
larger enough to make it important to screen for.  
The screening was done by a single question, which may have a specificity 
that is too low. It could potentially be improved by excluding worries about being too 
fat or overweight, which is unlikely to lead to a diagnosis of BDD. Further research is 
required to not only screen all inpatients but to determine if those identified with BDD 
can be engaged in Cognitive Behavior Therapy which is specific to BDD (Veale et al., 
2014; Veale et al., 1996b; Wilhelm et al., 2014) and/or a SSRI in the maximum 
tolerated dose (Phillips et al., 2002) and to the determine the treatment outcome as 
controlled trials tend to recruit those who are aware of the diagnosis and have sought 
help.  
Of note is that the majority of patients identified in this and previous studies 
had either a comorbid diagnosis of depression, substance misuse or an anxiety 
disorder. This implies that screening might be best targeted at those who present with 
such diagnoses either in an inpatient or community setting.   
Limitations: There was no formal screening with a structured diagnostic 
interview for other problems that puts the prevalence of BDD in the context of other 
unidentified diagnoses. Not all patients were interviewed with the structured 
diagnostic interview for BDD and so we cannot calculate the exact sensitivity or 
specificity of the screening questionnaire. However we are reasonably confident that 
the screening had a high sensitivity (few false negatives) for diagnosing BDD as it is 
very unlikely that a person who answers negatively to the question about whether they 
were worried about their appearance could fulfil the diagnostic criteria for BDD. It is 
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possible that shame might prevent them from discussing their symptoms with the 
screening question but then they are also unlikely to reveal their symptoms with a full 
diagnostic interview.  The primary aim of this study was also to identify whether the 
diagnosis of BDD was being missed. Unfortunately, there were insufficient resources 
to conduct a full structured diagnostic interview for all admissions. Equally we did not 
determine whether the participants with BDD had a delusional subtype, which is an 
indicator of severity of symptoms. In those patients who volunteered weight or 
concerns about being too fat, the important diagnosis of anorexia nervosa or bulimia 
was excluded; some might have fulfilled a diagnosis of eating disorder not otherwise 
specified (DSMIV) or an atypical eating disorder (ICD10) but this was not the focus 
of this study. The diagnosis of BDD can however still occur in the context of anorexia 
nervosa or bulimia (for example a preoccupation with another body part other than 
weight or shape). We used a clinical judgment in the SCID for determining whether a 
patient had a perceived defect and did not use a defect rating scale to operationalize 
the criterion (Stangier et al., 2000). Lastly we cannot exclude an interviewer bias in 
the use of the SCID for BDD.  
This study was conducted in a private psychiatric hospital in the UK. The 
prevalence of BDD is likely to be lower in a state (National Health Service) 
psychiatric in-patient hospital where there is a higher prevalence of psychosis. 
Whatever the prevalence rate in a particular setting, the clinical implications are that 
because patients do not reveal their symptoms of BDD, then screening should occur 
and especially in those who present with depression, substance misuse or an anxiety 
disorder. We demonstrated that this could be done by a single screening question that 
was acceptable to patients. Alternatively, screening for BDD can be done by a 
validated screening questionnaire (Cash et al., 2004; Veale et al., 2012).  
Conclusions: Whilst awareness of BDD in the general public may improve 
over time, it can still shameful for an individual to reveal their symptoms even when it 
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is their biggest problem. Thus it is the responsibility of a mental health professional 
to screen for BDD in the way that it is important to ask about an alcohol history or 
thoughts of suicide – issues that patients are often ashamed about and do not volunteer 
in their history without gentle probing. Further research needs to understand why 
professionals do not conduct a broader diagnostic interview – too often an assessment 
is limited to a patient’s history, mental state examination and risk assessment. At the 
very least this should be done in patients who present with substance misuse, 
depression or an anxiety disorder otherwise patients may continue to be treated 
inappropriately. Further research is required to determine the sensitivity and 
specificity of a screening question or questionnaire by interviewing all patients 
(irrespective of whether they score positively) with a full SCID.  
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Table 1:  Characteristics of four inpatient psychiatric samples assessing BDD 
prevalence. All values unless indicated refer to N (%) 
 
 
 
 Present study Kollei et al., 
(2011) 
Conroy et al., 
(2008) 
Grant et al., 
(2001) 
Country England Germany USA USA 
Sample size 432 155 100 101 
Current BDD 25 (5.8%) 3 (1.9%) 11 (11%) 13 (12.9%) 
95% C.I. 3.6%-8.1% 0.4-5.8% 5.2-17.4% 6.3-19.1% 
 
Lifetime BDD 
 
- 
 
4 (2.6) 
 
16 (16.0) 
 
- 
95% C.I. - 0.1-5.1% 8.7-23.3% - 
 
Age, years, mean (SD) 
 
40.4 (14.3) 
 
39.3 (13.6) 
 
39.5 (12.7) 
 
38.4 (10.1) 
Age range  17-80     
Female 224 (51.9) 95 (61.3) 67 (67.0) 65 (53.3) 
 
Diagnoses: 
Psychotic disorder 18 (4.2) 12 (7.7) 15 (15.0) 20 (16.4) 
Mood disorder 186 (43.0) 69 (44.5) 76 (76.0) 92 (75.4) 
Substance use disorder 162 (37.5) 16 (10.3) 2 (2.0) 62 (50.8) 
Anxiety disorder 49 (11.3) 25 (16.1) 3 (3.0) 6 (4.9) 
Somatoform disorder 0 (0.0) 3 (1.9) 0 (0.0) 1 (0.8) 
Eating disorder 2 (0.5) 14 (9.0) 2 (2.0) 9 (7.4) 
Adjustment disorder 8 (1.9) 0 (0.0) 1 (1.0) 2 (1.6) 
Personality disorder 4 (0.9) 12 (7.7) 1 (1.0) 0 (0.0) 
Impulse-control 
disorder 
0 (0.0) 1 (0.6) 0 (0.0) 6 (4.9) 
ADHD 0 (0.0) 1 (0.6) 0 (0.0) 2 (1.6) 
Other disorder 3 (0.7) 1 (0.6) 0 (0.0) 5 (4.1) 
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Table 2 Reasons provided by patients for not disclosing symptoms of BDD 
 
n Reason 
22 Felt ashamed, embarrassed or weak to discuss it 
11 Thought the problem was their appearance 
10 Did not know where to seek help 
  9 Did not know that such a problem existed  
  5 Wanted to ignore the problem  
  3 Did not want their family doctor to find out  
  1 Did not want their family to find out 
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Highlights 
432 admissions were screened on an adult psychiatric ward 
A screening question and a diagnostic interview for BDD was used 
Prevalence of Body Dysmorphic Disorder (BDD) was 5.8% (C.I. 3.6-8.1%) 
BDD occurred in those with depression, substance misuse or anxiety disorder 
If no screening was conducted then BDD would not have been detected  
